Identify new business opportunities for QIAGEN's consulting services business in North America.

Active participant in the Pistoia Alliance FAIR data working groups, their pharma council, and steering committee where members from diverse backgrounds from within pharma and related disciplines analyze common data centric problems in pharmaceutical industry and make recommendations on actionable projects to solve common issues. We assist the Advisory Board in strategy and direction in terms of shaping and facilitating projects to drive greater collaboration and innovation throughout drug discovery communities.

I am a senior consultant on the DaaS (data as a service) team providing technical and business expertise for customers engaged in either new and current data licensing agreements with Elsevier's scientific literature database portfolio (Science Direct, Scopus, Reaxys, Reaxys Medicinal Chemistry, Pharmapendium, Embase, and RESNET) which is focused on life sciences including pharma drug discovery and development R&D, biotechnology, material science, and diverse chemicals. Skillsets include extensive knowledge of datasets required primarily for drug discovery and development R&D and clinical projects, advanced technical knowledge in data science, and extensive experience in the sales process from prospecting to agreements.

In this role I consulted current Elsevier customers on how to better utilize the web-based applications Reaxys, Reaxys Medicinal Chemistry, Pharmapendium, Embase, and Pathway Studio to help drive their current life science R&D projects forward by meeting their information needs.

Business development for WuXi's FTE and FFS chemistry CRO business unit.

I have worked on many successful projects that have posed significant obstacles in taking a compound from an initial screening hit to NME declaration. These obstacles have included IP, synthetic, ADME, and potency issues that have required innovative solutions to solve these complex problems.My most recent position was held at Johnson & Johnson as a Scientist (Ph.D.) level medicinal chemist on a target based project in the therapeutic area of pain. My responsibilities included working independently within a multidisciplinary team setting on the design, synthesis, and evaluation of novel molecular entities directed at a pain target. This position required the use of all relevant synthetic, analytical, and modeling techniques to design, synthesize, purify, and characterize chemical compounds directed at known therapeutic targets.Prior to this project I was working in the therapeutic area of inflammation and bone reabsorbtion on the design and synthesis of small molecules directed at the inhibition of the protein kinase c-FMS . Again, this position required the use of all relevant synthetic, analytical, and modeling techniques to design, synthesize, purify, and characterize chemical compounds directed at known therapeutic targets.Previous to this position, I worked in a hit to lead group were my responsibilities were to evaluate screening hits, prioritize them based on activity, IP space, and synthetic feasibility, then through an iterative process convert these screening hits into viable leads and further to clinical candidates.

My position was to act as a liaison between the high throughput chemistry group, informatics, and computational chemistry departments to help manage and mine the large amount of data being generated for our internal chemistry libraries as well as the purchase and data management of external chemical libraries.My main accomplishment while in this position was the design and implementation of software and the underlying database used to gather, store, manipulate, and retrieve all data associated with high throughput chemistry libraries synthesized at 3DP. This data included plate and well assignments of all compounds synthesized, all monomers used in each reaction including amounts of each monomer used, LC/MS data, final structures, final weights, yields, and purity. The data generated was then stored in Oracle and retrieved then manipulated to find all compounds pure enough to register. Compounds were assigned new plate locations, new barcodes were assigned, and then were registered right from the software. All files necessary to run the Bohdan weighing station were generated to weigh the vials and move the pure compounds to new plate locations.Compounds that required purification were assigned new plate locations by the software and then purified via high throughput HPLC. Compound purity was determined using LC/MS, weighed, and registered.My other responsibilities included the generation and management of all virtual libraries associated with each new chemical library and the subsequent physical library selections. This included the determination of all monomers used for the library synthesis tailored specifically to the chemistry used in library production. I was also responsible for the writing of all protocols used in synthesizing the libraries.

I worked in the high throughput chemistry group were I was responsible for the design and synthesis of chemical libraries using all available parallel synthesis methods available.Our group was responsible for the design and synthesis of chemical libraries against targets from external collaborators. Library design was achieved using our in house directed diversity suite to build virtual libraries. Selections were made from the virtual libraries to synthesize a subset of the virtual library using criteria such as lipinski parameters.

I worked in the high throughput chemistry group were I was responsible for the design and synthesis of chemical libraries using their proprietary mix and split synthesis method involving their proprietary tagging method and photo labile linkers.

I was involved in two main projects in medicinal chemistry working on therapeutic targets. The first was the design and synthesis of peptidomimetics directed at the cysteine protease IL1B protease and the second was the design and synthesis of small molecules directed at the inhibition of the serine protease Thrombin.This position required the use of all relevant synthetic, analytical, and modeling techniques to design, synthesize, purify, and characterize chemical compounds directed at known therapeutic targets.While working on Thrombin, I utilized my cheminformatics and molecular modeling background to determine the binding confirmation of our current mechanism based inhibitor and using the molecular mechanics program Sparta determined the charges on a key bond attacked by Thrombin's serine triad. This lead to the design of better mechanism based inhibitors with a more potent Ki that were more stable and possessed better ADME properties.Prior to this I was working as a cheminformatics specialist managing our MDL databases and our chemical inventory system. I was also involved in a project with the IL-1beta protease project were I compared the x-ray crystal structures from the PDB of many known cysteine and serine proteases with bound inhibitors and determined that they all shared a common theme of binding in a beta sheet confirmation. Subsequent design of various peptidomimetics based on this information and applying them to our current peptide based inhibitors lead us to discover novel non-peptide based small molecule inhibitors of IL-1beta protease.I also worked on a project involving the addition of 5,000 - 50,000 MW PEG to the enzyme superoxide dismutase. Superoxide dismutase is an enzyme which soaks up free radicals and could be useful in head trauma by scavenging free radicals. The theory was that polyethylene glycol polymer addition would avoid ADME issues involved with the enzyme being delivered to the brain.

I was involved in two main projects in medicinal chemistry working on therapeutic targets. The first was the design and synthesis of small molecules directed at the inhibition of PLA2 in the area of inflammation and the second was the design and synthesis of analogs of Rapamycin as an immunosupressant.This position required the use of all relevant synthetic, analytical, and modeling techniques to design, synthesize, purify, and characterize chemical compounds directed at known therapeutic targets.